FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients set themselves a target date for quitting and will usually start taking Champix one to two weeks before this date.
Estonian: Patsiendid määravad kindlaks suitsetamisest loobumise kuupäeva ja alustavad tavaliselt Champixi manustamist 1-2 nädalat enne seda kuupäeva.
English: For more information about treatment with Champix, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Champixiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The percentage of patients who had not smoked at all during weeks 9-12 was 44% with Champix, 30% with bupropion, and 18% with placebo.
Estonian: Nende patsientide osakaal, kes ei olnud 9.-12. nädalani suitsetanud, oli Champixi korral 44%, bupropiooni korral 30% ja platseebo korral 18%.
English: In the study where patients were allowed to set their own target dates, Champix was also shown to be effective in helping patients to quit.
Estonian: Uuringus, kus patsiendid said ise määrata oma suitsetamisest loobumise kuupäevad, osutus Champix patsientide suitsetamisest loobumise vahendina samuti efektiivseks.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Champix, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Champixi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: The percentage in the patients who had taken bupropion was 16%.
Estonian: Bupropiooni kasutanud patsientide hulgas oli mittesuitsetajaid selleks ajaks 16%.
English: For the full list of all side effects and restrictions with Champix, see the package leaflet.
Estonian: Champixi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: In two main studies 2,052 smokers received 12-week treatment with Champix, bupropion (another non-nicotine medicine) or placebo (a dummy treatment).
Estonian: Kahes põhiuuringus said 2052 suitsetajat 12 ravinädala jooksul Champixit, bupropiooni (teatud nikotiinita ravim) või platseebot (näiv ravim).
English: More patients remained non-smokers after treatment with Champix than after placebo: 40 weeks after the end of the treatment period, the percentage of patients who were still non-smokers was 23% among those who had taken Champix, and 9% among those who had taken a placebo.
Estonian: Pärast ravi Champixiga jäi rohkem patsiente mittesuitsetajateks kui platseebo korral: 40 nädalat pärast ravikuuri lõppu oli Champixit kasutanute seas mittesuitsetajaid 23% ja platseebot kasutanute seas 9%.
English: Patients who are unwilling or unable to set a target date within one to two weeks could be offered the treatment first and then later choose their target date to fall within five weeks of starting treatment.
Estonian: Patsiendid, kes ei soovi või ei suuda määrata suitsetamisest loobumise kuupäeva 1-2 nädala jooksul, võivad saada esiteks ravi ja valida hiljem suitsetamisest loobumise kuupäeva, mis peab olema viie nädala jooksul alates ravi alustamisest.
English: Another study compared Champix with placebo in patients who were allowed to choose their own target dates for quitting, which could be between one week and five weeks of starting treatment.
Estonian: Teises uuringus võrreldi Champixit platseeboga patsientidel, kes said ise valida oma suitsetamisest loobumise kuupäevad, määrates need ajavahemikuks 1-5 nädalat alates ravi alustamisest.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Champix.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: People who smoke become addicted to nicotine, a chemical in tobacco.
Estonian: Suitsetajatel tekib sõltuvus tubakas sisalduvast keemilisest ainest nikotiinist.
English: In both studies, Champix was more effective than bupropion or placebo in helping patients to stop smoking.
Estonian: Mõlemas uuringus oli Champix patsientide suitsetamisest loobumise abistava vahendina efektiivsem kui bupropioon või platseebo.
English: What is the risk associated with Champix?
Estonian: Mis riskid Champixiga kaasnevad?
English: Nicotine acts in the nervous system, where it binds to receptors and triggers the release of a chemical messenger, dopamine, which plays a part in the pleasure derived from smoking.
Estonian: Nikotiin mõjub närvisüsteemile, kus see seondub retseptoritega ja vallandab keemilise virgatsaine dopamiini, mille tulemusena tekib mõnutunne.
English: When binding to these receptors, varenicline acts in two ways: it acts like nicotine (partial agonist) and this helps to relieve craving symptoms, but it also acts against nicotine (antagonist), by taking its place, and this helps to reduce the pleasurable effects of smoking.
Estonian: Champixi toimeaine varenikliin seondub mõnedega neist retseptoritest - α4β2-nikotiinatsetüülkoliini retseptoritega - ja toimib kahel viisil: sarnaselt nikotiinile (osalise agonistina), mis aitab himustussümptomeid leevendada, samuti nikotiinivastaselt (antagonistina), asendades seda, mis aitab vähendada suitsetamise meeldivust.
English: What is Champix?
Estonian: Mis on Champix?
English: Why has Champix been approved?
Estonian: Miks Champix heaks kiideti?
English: How does Champix work?
Estonian: Kuidas Champix toimib?
English: What benefit has Champix shown during the studies?
Estonian: Milles seisneb uuringute põhjal Champixi kasulikkus?
English: What is Champix used for?
Estonian: Milleks Champixit kasutatakse?
English: How is Champix used?
Estonian: Kuidas Champixit kasutatakse?
English: For patients who have successfully stopped smoking after 12 weeks of treatment, doctors may choose to carry on treatment for another 12 weeks.
Estonian: Arst võib otsustada jätkata veel 12 nädala jooksul nende patsientide ravi, kes on 12 nädalat pärast ravi alustamist suitsetamisest edukalt loobunud.
English: How has Champix been studied?
Estonian: Kuidas Champixit uuriti?
English: Both active substances have been available in the EU for a number of years: lamivudine has been authorised as Epivir since 1996 and zidovudine has been available in the EU since the mid-1980s.
Estonian: Mõlemat toimeainet on Euroopa Liidus turustatud aastaid: lamivudiin sai müügiloa ravimina Epivir 1996. aastal ja sidovudiini on turustatud Euroopa Liidus alates 1980. aastate keskpaigast.
English: The full EPAR for Lamivudine/Zidovudine Teva can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Lamivudine / Zidovudine Teva kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Therefore, the CHMP's view was that, as for Combivir, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Combiviri korral, ületab kasulikkus sellega kaasnevad riskid.
English: Lamivudine/Zidovudine Teva is a medicine that contains two active substances, lamivudine (150 mg) and zidovudine (300 mg).
Estonian: Lamivudine / Zidovudine Teva on ravim, mis sisaldab kaht toimeainet - lamivudiini (150 mg) ja sidovudiini (300 mg).
English: Patients who cannot swallow tablets may crush the tablets and add them to a small amount of food or drink immediately before swallowing it.
Estonian: Kui patsient ei suuda tablette neelata, tuleb lisada purustatud tabletid vahetult enne annuse võtmist väikesele söögi- või joogikogusele.
English: If patients need to stop taking lamivudine or zidovudine, or need to take different doses because of problems with their kidneys, liver or blood, they will need to take medicines containing lamivudine or zidovudine separately.
Estonian: Kui patsientidel on vaja neeru-, maksa- või verehäirete tõttu katkestada kas lamivudiini või sidovudiini kasutamine või nende annust muuta, peavad nad manustama lamivudiini või sidovudiini sisaldavaid ravimeid eraldi.
English: The recommended dose of Lamivudine/Zidovudine Teva for patients over 12 years of age who weigh at least 30 kg is one tablet taken twice a day.
Estonian: Lamivudine / Zidovudine Teva soovitatav annus vähemalt 12-aastastel patsientidel, kes kaaluvad vähemalt 30 kg on üks tablett kaks korda ööpäevas.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Lamivudine/Zidovudine Teva on 28 February 2011.
Estonian: Euroopa Komisjon andis Lamivudine / Zidovudine Teva müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 28. veebruaril 2011.
English: They both work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells and make more viruses.
Estonian: Mõlemad toimivad sarnaselt, blokeerides pöördtranskriptaasi (ensüüm, mida toodab HIV ja mis võimaldab viirusel rakke nakatada ja paljuneda) aktiivsust.
English: Children taking Lamivudine/Zidovudine Teva should be closely monitored for side effects.
Estonian: Lamivudine / Zidovudine Tevat kasutavaid lapsi tuleb hoolikalt jälgida kõrvalnähtude suhtes.
English: In children (below 12 years of age) weighing between 14 and 30 kg, the number of tablets and half tablets to take depends on their weight.
Estonian: 14-30 kg kaaluvate alla 12-aastaste laste annus (tervete või poolte tablettide arv) oleneb kehakaalust.
English: Lamivudine/Zidovudine Teva does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Estonian: See ei ravi HIV-nakkust ega AIDS-i välja, kuid võib edasi lükata immuunsüsteemi kahjustumist ning AIDS-iga seotud nakkuste ja haiguste teket.
English: Children weighing less than 14 kg will need to use separate oral solutions containing lamivudine and zidovudine.
Estonian: Alla 14 kg kaaluvatel lastel tuleb kasutada spetsiaalseid lamivudiini ja sidovudiini sisaldavaid suukaudseid lahuseid.
English: For more information about treatment with Lamivudine/Zidovudine Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Lamivudine / Zidovudine Tevaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Lamivudine/Zidovudine Teva.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Lamivudine/Zidovudine Teva lamivudine/zidovudine
Estonian: Lamivudine / Zidovudine Teva lamivudiin/sidovudiin
English: This means that Lamivudine/Zidovudine Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Combivir.
Estonian: See tähendab, et Lamivudine / Zidovudine Teva on sarnane võrdlusravimiga Combivir, millel juba on Euroopa Liidus müügiluba.
English: Treatment with Lamivudine/Zidovudine Teva should be started by a doctor who has experience in the management of HIV infection.
Estonian: Ravi Lamivudine / Zidovudine Tevaga peab alustama HIV-nakkuse ravis kogenud arst.
English: Because Lamivudine/Zidovudine Teva is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Lamivudine / Zidovudine Teva on geneeriline ravim, peetakse ravimi kasulikkust ja riske samadeks mis võrdlusravimil.
English: The CHMP concluded that, in accordance with EU requirements, Lamivudine/Zidovudine Teva has been shown to have comparable quality and to be bioequivalent to Combivir.
Estonian: Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Lamivudine / Zidovudine Teva võrdväärne kvaliteet ja bioekvivalentsus ravimiga Combivir.
English: Because Lamivudine/Zidovudine Teva is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Combivir.
Estonian: Et Lamivudine / Zidovudine Teva on geneeriline ravim, piirdusid uuringud katsetega, milles näidati ravimi bioekvivalentsust võrdlusravimiga Combivir.
English: The Committee recommended that Lamivudine/Zidovudine Teva be given marketing authorisation.
Estonian: Komitee soovitas anda Lamivudine / Zidovudine Teva müügiloa.
English: Lamivudine/Zidovudine Teva, taken in combination with at least one other HIV medicine, reduces the amount of HIV in the blood and keeps it at a low level.
Estonian: Vähemalt ühe muu HIV-ravimiga koos manustatav Lamivudine / Zidovudine Teva vähendab HIVi kogust veres ja hoiab selle sisalduse väikese.
English: Lamivudine/Zidovudine Teva is a ‘generic medicine'.
Estonian: Lamivudine / Zidovudine Teva on geneeriline ravim.
English: Lamivudine/Zidovudine Teva is used in combination with at least one other HIV medicine to treat patients infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: Seda kasutatakse koos vähemalt veel ühe HIV-ravimiga, et ravida patsiente, kellel on inimese immuunpuudulikkuse viiruse (HIV) nakkus.
English: This is a summary of the European public assessment report (EPAR) for Lamivudine/Zidovudine Teva.
Estonian: Käesolev dokument on ravimi Lamivudine / Zidovudine Teva Euroopa avaliku hindamisaruande kokkuvõte.
English: Other information about Lamivudine/Zidovudine Teva
Estonian: Muu teave Lamivudine / Zidovudine Teva kohta
English: Both active substances in Lamivudine/Zidovudine Teva, lamivudine and zidovudine, are nucleoside reverse transcriptase inhibitors (NRTIs).
Estonian: Lamivudine / Zidovudine Teva mõlemad toimeained lamivudiin ja sidovudiin on nukleosiidpöördtranskriptaasi inhibiitorid, mis blokeerivad ensüümi pöördtranskriptaasi toime.
English: What is Lamivudine/Zidovudine Teva?
Estonian: Mis on Lamivudine / Zidovudine Teva?
English: Why has Lamivudine/Zidovudine Teva been approved?
Estonian: Miks Lamivudine / Zidovudine Teva heaks kiideti?
English: How does Lamivudine/Zidovudine Teva work?
Estonian: Kuidas Lamivudine / Zidovudine Teva toimib?
English: How is Lamivudine/Zidovudine Teva used?
Estonian: Kuidas Lamivudine / Zidovudine Tevat kasutatakse?
English: What is Lamivudine/Zidovudine Teva used for?
Estonian: Milleks Lamivudine / Zidovudine Tevat kasutatakse?
English: How has Lamivudine Zidovudine Teva been studied?
Estonian: Kuidas Lamivudine / Zidovudine Tevat uuriti?
English: What are the benefits and risks of Lamivudine/Zidovudine Teva?
Estonian: Milles seisneb Lamivudine / Zidovudine Teva kasulikkus ja mis riskid ravimiga kaasnevad?
English: Ref.: EMEA/484536/2009 EMEA/H/C/1018
Estonian: Viide: EMEA/484536/2009 EMEA/H/C/1018
English: It is available as white capsules (200 mg).
Estonian: Seda turustatakse valgete kapslitena (200 mg).
English: This summary was last updated in 09-2009.
Estonian: Kokkuvõtte viimane uuendus: 09-2009
English: The duration of treatment depends on the patient's condition and response to treatment, and ranges from 24 weeks to a year.
Estonian: Ravi kestus sõltub patsiendi seisundist ja ravivastusest ning võib ulatuda 24 nädalast ühe aastani.
English: The European Commission granted a marketing authorisation valid throughout the EU for Ribavirin Teva to Teva Pharma B.V. on 31 March 2009.
Estonian: Euroopa Komisjon andis Ribavirin Teva müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Teva Pharma BV 31. märtsil 2009.
English: It can also be used in adults who previously responded to treatment with interferon alfa but whose disease has come back.
Estonian: Seda võib kasutada ka täiskasvanutel, kelle haigus allus ravile alfainterferooniga, kuid hiljem taastus.
English: Ribavirin Teva must never be used on its own but only together with interferon alfa-2b (another medicine used in hepatitis).
Estonian: Ribavirin Tevat ei tohi kunagi kasutada ainsa ravimina, vaid ainult koos alfa-2b-interferooniga (samuti hepatiidiravim).
English: The Committee recommended that Ribavirin Teva be given marketing authorisation.
Estonian: Komitee soovitas anda Ribavirin Tevale müügiloa.
English: The dose of Ribavirin Teva is based on the patient's body weight, and ranges from three to seven capsules a day.
Estonian: Ribavirin Teva annus põhineb patsiendi kehakaalul ja on 3-7 kapslit päevas.
English: Ribavirin Teva is thought to interfere with the production or action of viral DNA and RNA, which are needed for viruses to survive and multiply.
Estonian: Arvatakse, et Ribavirin Teva häirib viiruste püsimiseks ja paljunemiseks vajaliku viiruse-DNA ja -RNA teket või toimet.
English: The full EPAR for the reference medicine can also be found on the Agency's website.
Estonian: Euroopa avaliku hindamisaruande täisteksti võrdlusravimi kohta leiate samuti Euroopa Ravimiameti veebilehelt.
English: Ribavirin Teva on its own has no effect on eliminating the hepatitis C virus from the body.
Estonian: Ribavirin Teva ainsa ravimina ei mõjuta C-hepatiidi viiruse kõrvaldamist organismist.
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Ribavirin Teva has been shown to have comparable quality and to be bioequivalent to Rebetol.
Estonian: Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele on tõendatud Ribavirin Teva võrdväärne kvaliteet ja bioekvivalentsus ravimiga Rebetol.
English: Therefore, the CHMP's view was that, as for Rebetol, the benefit outweighs the identified risk.
Estonian: Sel põhjusel arvas inimravimite komitee, et nagu ka Rebetoli puhul, ületab ravimi kasulikkus sellega kaasnevad riskid.
English: Because Ribavirin Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Estonian: Et Ribavirin Teva on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Ribavirin Teva is a ‘generic medicine'.
Estonian: Ribavirin Teva on geneeriline ravim.
English: Ribavirin Teva is used to treat patients aged three years and older who have chronic (long-term) hepatitis C (a disease of the liver due to an infection with the hepatitis C virus).
Estonian: Ribavirin Tevat kasutatakse kroonilise (pikaajalise) C-hepatiidi (C-hepatiidi viiruse nakkusest põhjustatud maksahaigus) raviks vähemalt 3-aastastel patsientidel.
English: Ribavirin Teva ribavirin
Estonian: Ribavirin Teva ribaviriin Kokkuvõte üldsusele
English: This means that it is similar to a ‘reference medicine' already authorised in the European Union (EU) called Rebetol.
Estonian: See tähendab, et Ribavirin Teva on sarnane võrdlusravimiga Rebetol, millel juba on Euroopa Liidus müügiluba.
English: Why has Ribavirin Teva been approved?
Estonian: Miks Ribavirin Teva heaks kiideti?
English: Because Ribavirin Teva is a generic medicine, studies have been limited to tests to demonstrate that it is bioequivalent to the reference medicine.
Estonian: Et Ribavirin Teva on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Ribavirin Teva bioekvivalentsust võrdlusravimiga.
English: Ribavirin Teva is a medicine that contains the active substance ribavirin.
Estonian: Ribavirin Teva on ravim, mis sisaldab toimeainena ribaviriini.
English: What is Ribavirin Teva?
Estonian: Mis on Ribavirin Teva?
English: Other information about Ribavirin Teva:
Estonian: Muu teave Ribavirin Teva kohta
English: The full EPAR for Ribavirin Teva can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Ribavirin Teva kohta leiate siit.
English: Ribavirin Teva is taken with food each day in two divided doses (morning and evening).
Estonian: Ravimit võivad võtta ainult patsiendid, kes kaaluvad vähemalt 47 kg. Ribavirin Tevat manustatakse iga päev koos toiduga, jagades annuse kahte ossa (hommikul ja õhtul).
English: The active substance in Ribavirin Teva, ribavirin, is an antiviral belonging to the class ‘nucleoside analogues'.
Estonian: Ribavirin Teva toimeaine ribaviriin on nukleosiidianaloogide klassi kuuluv viiruseravim.
English: Ribavirin Teva can be used in ‘naïve' patients (who have not been treated before) for all types of hepatitis C except for genotype 1.
Estonian: Ribavirin Tevat saab kasutada varem ravimata patsientidel mis tahes liiki C-hepatiidiga (v.a 1. genotüübiga C-hepatiit) patsientide raviks.
English: The dose may need to be adjusted for patients who experience side effects.
Estonian: Kõrvalnähtude ilmnemisel võib olla vaja ravimi annust kohandada.
English: How has Ribavirin Teva been studied?
Estonian: Kuidas Ribavirin Tevat uuriti?
English: Treatment with Ribavirin Teva should be started and monitored by a doctor who has experience in the management of chronic hepatitis C.
Estonian: Ravi Ribavirin Tevaga võib alustada üksnes kroonilise C-hepatiidi ravis kogenud arst ning see ravi peab toimuma tema järelevalve all.
English: What are the benefit and risk of Ribavirin Teva?
Estonian: Milles seisneb Ribavirin Teva kasulikkus ja mis riskid ravimiga kaasnevad?
English: What is Ribavirin Teva used for?
Estonian: Milleks Ribavirin Tevat kasutatakse?
English: How is Ribavirin Teva used?
Estonian: Kuidas Ribavirin Tevat kasutatakse?
English: How does Ribavirin Teva work?
Estonian: Kuidas Ribavirin Teva toimib?
English: ATCvet code: QP54AA05.
Estonian: ATC-vet kood: QP54AA05.
English: The product is a skin and eye irritant.
Estonian: Toode on naha ja silmade ärritav.
English: Each single-dose (pipette) delivers:
Estonian: Iga üksik annus (pipett) annab:
English: Date of first authorisation: 17/04/2019
Estonian: Esmase müügiloa väljastamise kuupäev: 17/04/2019
English: On the day of treatment, children must not handle treated animals and the animals should not be permitted to sleep with their owners, especially children.
Estonian: Ravi päeval ei tohi lapsed ravitud loomi katsuda ja loomad ei tohi magada omanike, eriti laste juures.
English: Do not administer orally or parenterally.
Estonian: Ärge manustage oraalselt või parenteraalselt.
English: Periodic safety update report (PSUR) submissions shall be synchronised and submitted at the same frequency as for the reference product.
Estonian: Perioodiline ajakohastatud ohutusaruande esitamine sünkroniseeritakse ja esitatakse samal sagedusel kui võrdlustoodete puhul.
English: Do not use in animals under 6 weeks of age.
Estonian: Mitte kasutada alla 6 nädala vanustel loomadel.
English: Incompatibilities Not applicable.
Estonian: Sobimatus Ei kohaldata.
English: Clear colourless to yellow solution.
Estonian: Selge värvitu kuni kollane lahus.
English: Images for optional inclusion should space allow
Estonian: Pilte vabatahtlikuks kaasamiseks tuleks ruumi lubada
English: A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.
Estonian: 30 päeva pärast ravi on soovitatav teha uus veterinaarne läbivaatus, sest mõned loomad võivad vajada teistkordset ravi.
English: Pharmacotherapeutic group: antiparasitic products, insecticides and repellents, macrocyclic lactones.
Estonian: Farmakoterapeutiline rühm: parasiitide vastased ained, insektitsiidid ja repellendid, makrotsüklilised laktoonid.
English: 60/120 Appropriate combination of pipettes
Estonian: 60/120 Sobiv pipettide kombinatsioon
English: Used applicators should be disposed of immediately and not left within the sight or reach of children.
Estonian: Kasutatud pakendid tuleb kohe ära visata ja mitte jätta lastele kättesaadavasse või nähtavasse kohta.
English: Butylated hydroxytoluene (E321) 0.08%.
Estonian: Butüülhüdroksütolueen (E321) 0,08%
English: 3 pipettes 6 pipettes
Estonian: 3 pipetti 6 pipetti